Praxis Precision Medicines, Inc. PRAX
As ofNov 20, 2026, 2:50 PM EST
- YTD
- +3.28%
- 1 year
- +85.51%
5D -24.62 (-7.48%)
- Market cap
- 8.52B
- EPS (ttm)
- -12.82
- Shares out
- 27.95M
- Forward P/E
- -31.69
- YTD return
- +3.28%
- 1-year return
- +85.51%
- 50-day average
- 287.32
- 200-day average
- 314.51
- Enterprise value
- 7.79B
- Price / book
- 6.90
- Volume
- 504.41K
- Avg volume
- 473.73K
- Open
- 304.98
- Previous close
- 310.90
- Day's range
- 303.13 – 308.61
- 52-week range
- 164.09 – 386.33
- Beta
- 2.84
- Analysts
- Strong Buy
- Price target
- 674.43 (+121.6%)
- Earnings date
- Feb 18, 2027
Key statistics
- Free cash flow
- -214.15M
- Total cash
- 745.32M
- Total debt
- 732.00K
- Return on equity
- -44.84%
- Short % of float
- 15.09%
Fundamental scorecard
4 of 25 checks passed on PRAX’s reported financials
4of 25 checks passed
- Value 0 of 5
- Growth 1 of 5
- Profitability 0 of 5
- Financial health 3 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Analyst view
Consensus: strong buy
- Target (low)
- 189.00
- Target (mean)
- 674.43
- Target (high)
- 1,201.00
- Strong buy3
- Buy15
- Hold0
- Sell1
- Strong sell0
Next earnings
Feb 18, 2027
Expected Feb 18, 2027. Consensus EPS estimate -3.63.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 18, 2027 | Dec 30, 2026 | -4.08 | — | — | — |
| Nov 9, 2026 | Sep 30, 2026 | -3.54 | -3.23 | +0.31 | +8.76% |
| Aug 6, 2026 | Jun 30, 2026 | -3.67 | -2.87 | +0.80 | +21.80% |
| May 7, 2026 | Mar 31, 2026 | -3.58 | -3.20 | +0.38 | +10.61% |
| Feb 19, 2026 | Dec 31, 2025 | -3.13 | -3.50 | -0.37 | -11.97% |
| Nov 5, 2025 | Sep 30, 2025 | -3.45 | -3.36 | +0.09 | +2.61% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 17, 2026 | Wells Fargo | up | Equal-Weight | Overweight |
| Nov 16, 2026 | Guggenheim | main | Buy | Buy |
| Nov 16, 2026 | Baird | main | Outperform | Outperform |
| Nov 10, 2026 | RBC Capital | main | Outperform | Outperform |
| Nov 10, 2026 | Wedbush | main | Underperform | Underperform |
| Nov 10, 2026 | Wells Fargo | main | Equal-Weight | Equal-Weight |
About Praxis Precision Medicines, Inc.
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance in the United States. The company's platforms include Cerebrum, a small molecule platform for CNS small molecule therapies to develop orally available precision therapies; and Solidus to discover and develop antisense oligonucleotide. It also develops ulixacaltamide, a small molecule inhibitor of T-type calcium channels that in NDA for the treatment of essential tremor; relutrigine, a small molecule, which is in NDA for the treatment of SCN2A- and SCN8A-developmental and epileptic encephalopathies (DEE), as well as in Phase 3 trial for broad DEEs; vormatrigine, a small molecule targeting the hyperexcitable state of sodium-channels in the brain that is in Phase 3 trial for the treatment of adjunctive focal epilepsy, as well as in Phase 2 trial for monotherapy focal epilepsy; and Elsunersen, a clinical-stage ASO designed to selectively decrease SCN2A gene expression, which is in Phase 3 trial for the treatment of SCN2A-DEE. In addition, the company is developing product candidates in pre-clinical trial comprising PRAX-020 to treat KCNT1; PRAX-080 that targets PCDH19 mosaic expression disorders; PRAX-090 for targeting SYNGAP1 loss-of-function; and PRAX-100 that targets SCN2A LoF mutations. It has a cooperation and license agreement with RogCon Inc.; research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and research collaboration and license agreement to develop an iontophoretic transdermal patch for the delivery of ulixacaltamide. The company was formerly known as EpiPM Therapeutics, Inc. and changed its name to Praxis Precision Medicines, Inc. in October 2016. Praxis Precision Medicines, Inc. was incorporated in 2015 and is headquartered in Boston, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- praxismedicines.com
News
JP Morgan Maintains Overweight on Praxis Precision Medicine, Raises Price Target to $725
This STMicroelectronics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday B. Riley Securities Initiates Coverage On Praxis Precision Medicine with Buy Rating, Announces Price Target of $713
Praxis Precision: Steady Hands For A Shaky PDUFA Season (Initiating With A Speculative Buy)
This Elevance Health Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday
This Medtronic Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday Wells Fargo Upgrades Praxis Precision Medicine to Overweight, Raises Price Target to $509
Praxis Precision Medicines, Inc. (PRAX) Presents at UBS Global Biopharma Conference 2026 Transcript Guggenheim Maintains Buy on Praxis Precision Medicine, Raises Price Target to $1050
Baird Maintains Outperform on Praxis Precision Medicine, Raises Price Target to $568
Your note
Sign in to keep a note on PRAX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ADAGE CAPITAL MANAGEMENT, L.P. | Beneficial Owner of more than 10% of a Class of Security | Sale | Oct 15, 2025 | 0 |
| ARBUCKLE STUART A | Director | Stock Award(Grant) | Jun 9, 2026 | 2,537 |
| KELLY TIMOTHY EDWIN | Chief Financial Officer | Stock Award(Grant) | May 13, 2026 | 31,167 |
| KINDLER JEFFREY B | Director | Stock Award(Grant) | Jun 9, 2026 | 2,537 |
| MASTROCOLA LAUREN | Officer | Stock Award(Grant) | May 13, 2026 | 13,572 |
| MITCHELL DEAN J | Director | Stock Award(Grant) | Jun 9, 2026 | 18,622 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Janus Henderson Group Ltd. | 12.34% | 3,449,950 | 1.07B | Sep 29, 2026 |
| FMR, LLC | 9.44% | 2,637,857 | 820.11M | Sep 29, 2026 |
| Blackrock Inc. | 7.99% | 2,232,814 | 694.18M | Sep 29, 2026 |
| Perceptive Advisors Llc | 7.24% | 2,024,781 | 629.50M | Sep 29, 2026 |
| Baker Bros. Advisors, LP | 6.27% | 1,753,198 | 545.07M | Sep 29, 2026 |
| Orbis Allan Gray Ltd | 4.87% | 1,360,049 | 422.84M | Sep 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.17% | 885,411 | 275.27M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.33% | 650,750 | 202.32M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 2.29% | 639,578 | 198.84M | Jun 29, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 1.53% | 427,949 | 133.05M | Sep 29, 2026 |
| Fidelity Select Portfolios-Select Biotechnology Portfolio | 1.46% | 409,429 | 127.29M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Value Index Fund | 1.45% | 405,016 | 125.92M | Jun 29, 2026 |
